ClinicalTrials.gg
Status unknownNCT05051930Updated Oct 25, 2021

A Clinical Trial of TQC3721 Suspension for Inhalation

A Phase 1 interventional study of TQC3721 suspension for inhalation and TQC3721 suspension placebo for inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Planned enrollment
8th of 17
114 · median 113
Started
2021
the only one that year
Phase 1
7 of 17
none open now
Registered
2nd of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 8th largest by planned enrollment, is the only one that started in 2021, is one of 7 in phase 1, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD)and asthma.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form before the trial, fully understand the content, process and possible adverse reactions of the test;
  • Able to complete the study according to the requirements of protocol;
  • Aged between 18 and 65 years old, both men and women;
  • For healthy subjects: Male ≥50kg, female ≥45kg,(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value); For patients: BMI is 18-28 kg/m2 (including the critical value), and body weight is ≥45kg.
  • For healthy subjects: normal or abnormal vital signs, physical examination, laboratory examination, , and imageological examination have no clinical significance;
  • For healthy subjects: and forced vital capacity(FVC) are at least 90% of the predicted values;
  • Subjects (including male subjects) have no pregnancy plan and have voluntarily taken effective measures for at least 1 month after being screened to the last use of the study drug;
  • For patients: Vital signs range: systolic blood pressure 90 to 140mmHg, diastolic blood pressure 50 to 90 mmHg, heart rate 50 to 90 bpm;
  • For patients: 12-lead electrocardiogram with corrected ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no morphologic and other clinical significant abnormalities (such as left band branch block, atrioventricular node dysfunction, ischemic ST segment abnormalities);
  • For patients: Ability to perform acceptable and reproducible spirometry;
  • For patients: According to the diagnostic criteria of 2018 Practical Edition of Guidelines for the Diagnosis and Treatment of , the patient was diagnosed with COPD for at least 1 year;Post-bronchodilator spirometry at screening must demonstrate FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal;
  • For patients: mMRC Scoring at screening ≥2;
  • For patients: Clinically stable COPD in the previous 4 weeks;
  • For patients: Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication;
  • For patients: Current and former smokers with a smoking history of ≥10 pack years(smoking at least 20 cigarettes a day for 10 years or at least 10 cigarettes a day for 20 years);
  • For patients: beta agonists are currently used only "when needed";
  • For patients: Never smoked or An ex-smoker for ≥6 months;

Exclusion criteria

Exclusion Criteria:

  • Preexisting or existing the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, immune system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator assesses that may affect drug metabolism or safety.
  • For healthy subjects: Have a history of fainting needles, fainting blood.
  • For healthy subjects: Known allergy to the study drug and their metabolites or any of the of the formulation.
  • For healthy subjects: Those who smoked more than 5 cigarettes per day during the 3 months before the trial.
  • A history of alcohol abuse in the past 6 months (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).
  • For healthy subjects: Donated blood or had substantial loss of blood (more than 400 mL) within 2 months before the test.
  • For healthy subjects: Had taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug.
  • Participated in other clinical trials within 3 months prior to this study.
  • Positive for hepatitis (including and C), (HIV) or syphilis at screening.
  • Women who are pregnant or breast-feeding.
  • Positive test for alcohol.
  • For healthy subjects: Blood collection is difficult or cannot tolerate venipuncture blood collection.
  • For healthy subjects: The subject is unable or can not comply with ward management regulations.
  • For healthy subjects: The subject is unable to complete the study due to personal reasons.
  • For healthy subjects: Any circumstances that the investigator considers to pose a safety risk to the subject during the study or may interfere with the conduct of the study.
  • For patients: Intolerance to salbutamol, tiotropium, or this product or prior exposure to Ensifentrine (RPL554).
  • For patients: Use of any medicine within 4 weeks prior to initiation of the study drug, including non-prescription medications and herbs, except vitamins.
  • For patients: Physical examination findings that researchers consider at the time of screening.
  • For patients: A history of cardiovascular disease (including arrhythmias) or active hyperthyroidism.
  • For patients: History of of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    TQC3721 suspension for inhalation

    Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation on Day 1.

    Drug: TQC3721 suspension for inhalation

  • Placebo comparator
    TQC3721 suspension placebo for inhalation

    Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation on Day 1.

    Drug: TQC3721 suspension placebo for inhalation

Interventions

  • Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.

  • DrugTQC3721 suspension placebo for inhalation

    Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    The Number of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

  2. Incidence of adverse events

    The Incidence of adverse events as assessed by CTCAE v5.0

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

  3. Number of adverse events related to the study drug

    The number of adverse events associated with the study drug assessed by CTCAE V5.0

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

  4. Incidence of adverse events associated with the study drug

    Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

  5. Area Under The Curve(AUC)

    Area under the curve

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

  6. Plasma drug peak concentration(Cmax )

    Plasma drug peak concentration

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

  7. Time to peak(Tmax)

    Time to maximum concentration following drug administration

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

Secondary outcomes

  1. Elimination half-life time(t1/2)

    Apparent terminal elimination half-life following drug administration

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

  2. Apparent volume of distribution(Vd)

    Apparent volume of distribution

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

  3. Clearance(CL)

    Clearance

    Time frame: Within 60 minutes before each administration, to 72 hours after administration

  4. Forced Expiratory Volume in the first second (FEV1) for patients with Chronic Obstructive Pulmonary Disease(COPD) or asthma

    Mean Change From Baseline in Peak FEV1 (Over 3 Hours)

    Time frame: From before administration to 3 hours after administration

  5. Mean Change From Baseline FEV1 to Morning Trough FEV1

    Mean Change From Baseline FEV1 to Morning Trough FEV1

    Time frame: From the enrollment of the subjects to to 72 hours after administration

  6. Mean Change From Baseline FEV1 to Average FEV1

    Mean Change From Baseline FEV1 to Average FEV1

    Time frame: From the enrollment of the subjects to to 72 hours after administration

  7. COPD Assessment Test (CAT) for patients with COPD

    Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week 4.The score range is 0 to 40 (0 to 10 is minor influence;11 to 20 is moderate; 21 to30 is severe;31 to 40 is very severe), and more than 10 indicates more symptoms.

    Time frame: From enrollment to 4 weeks after administration

  8. Modified medical research council(mMRC) for patients with COPD or asthma

    Mean Change From Baseline in mMRC Scoring at Week 4.The severity is measured on a five-point scale from 0 to 4, with a higher score indicating more severe respiratory distress.

    Time frame: From enrollment to 4 weeks after administration

07

Study locations

1 of 1 sites recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2022, 12 months after the start.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 12 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2021
First posted
Sep 21, 2021
StartActual
Oct 18, 2021
Primary completionEst.
Oct 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05051930
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Oct 18, 2021
Primary completion
Oct 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Oct 25, 2021

Study contacts

Weimin Li, Post Doctor
Contact
llllllv2@126.com
028-85423837

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion